Nura Pain Clinics Physician Treats First Patient in Minnesota with New Medtronic SynchroMed III Targeted Drug Delivery System for Pain

EDINA, Minn., Jan. 9, 2024 /PRNewswire/ -- Nura Pain Clinics, the Twin Cities' foremost multidisciplinary pain management clinic, announced today that the first patient in Minnesota has been implanted with the new Medtronic SynchroMed™ III implantable drug pump for the treatment of chronic pain. The implant procedure was performed by Nura's Dr. Erin Bettendorf, an experienced interventional pain management physician and Minneapolis native who graduated from Harvard Medical School.

The patient, Scott Thompson, had an injury many years ago that caused severe chronic pain that limited his daily functioning and prevented him from being able to fully participate in activities he enjoyed. Despite trying a wide variety of treatments over many years, he continued to have debilitating pain. Scott eventually underwent a trial for targeted drug delivery at Nura, where he experienced the best pain relief he had in years and chose to proceed with a permanent intrathecal pain pump implant. Following the surgery, he was pleased with how comfortable he felt. Scott is excited to continue to recover and start getting back to his favorite hobbies that he has missed.

"After 32 years of relentless, debilitating pain with no relief, I was given the gift of a brand-new start. Today, I was implanted with Medtronic's next-generation intrathecal pain pump which has already changed my life dramatically," said Thompson. "My life begins anew today, and I cannot wait to experience all that is ahead."

Medtronic announced FDA approval of the new SynchroMed III implantable drug delivery system in October 2023 for treatment of chronic and cancer pain. The system alleviates symptoms by delivering medication directly to the fluid surrounding the spinal cord. SynchroMed III is an upgraded system compared to the SynchroMed II system, featuring improved electronics with firmware capable of being updated after implant, additional protections for patient data through enhanced cybersecurity, and a new "refill only" physician workflow for more efficient programming. The system also carries forward several mid-generation durable design enhancements from the SynchroMed II pump which have contributed to the long-term safety and reliability of the device.¹

"At Nura, we focus on serving our patients with compassionate and individualized care and the most advanced technology, so I'm incredibly excited to be one of the first in the nation to provide this new pain management option to patients suffering from debilitating chronic pain, cancer pain or severe spasticity," said Dr. Bettendorf. "These patients have tried and exhausted many other options and Medtronic's new therapy offers pain relief and hope providing a better quality of life to those who so desperately need it."

Opioid abuse and misuse remains a significant problem. Targeted drug delivery therapy is a safe, proven and effective way to manage chronic pain, cancer pain or severe spasticity with greater efficacy, fewer side effects and a high degree of clinician control as compared to oral medication.^{2,3,4,5,6,7,8} The system delivers medication directly to the fluid surrounding the spinal cord via a catheter connected to a small, battery-powered programmable pump. Patients with the SynchroMed III system will continue to have access to diagnostic imaging through industry-leading 1.5T and 3T full-body MRI conditionality.⁹

At Nura, patients can receive a full range of care from medication management, physical therapy and behavioral health coordinated with minimally invasive interventional procedures all within the same practice. This is a critical advantage for patients who otherwise may receive fragmented pain management by multiple providers at multiple locations. For more complex chronic pain problems, Nura offers a full range of implantable pain control options including spinal cord stimulation and targeted spinal drug delivery devices including the SynchroMed III system. Nura's multidisciplinary approach also aims to dial down the need for opioids to treat pain.

For more information on Nura Pain Clinics and its focus on pain management, visit nuraclinics.com.

About Nura Pain Clinics
Nura (formally MAPS Medical Pain Clinics) was founded in 1995 by David Schultz, MD, a pioneer in interventional pain management. In his work as a practicing anesthesiologist in the 1990s, Dr. Schultz realized the need to treat chronic pain patients with a more comprehensive approach and went on to establish the region's first multidisciplinary pain management clinic, coordinating high tech interventional procedures with in-house physical therapy and psychology services. Nura is nationally recognized as a center of excellence for implantable pain control and one of the leading research centers in the U.S. for trials and implants of neuromodulation devices. Nura's mission is to improve the lives of people living with the most complex chronic pain through exceptional care.

References
¹ 2022 Product Performance Report
² Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13:1304-1313.
³ Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drugrelated toxicity, and survival. J Clin Oncol. 2002;20:4040-4049
⁴ Pope JE, Deer TR, Amirdelfan K, McRoberts WP, Azeem N. The Pharmacology of Spinal Opioids and Ziconotide for the Treatment of Non-Cancer Pain. Curr Neuropharmacol. 2017;15(2):206-216.
⁵ Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001;32(9):2099-2109.
⁶ Gilmartin R, Bruce D, Storrs BB, et al. Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial. J Child Neurol. 2000;15:71–77.
⁷ Meythaler JM, DeVivo MJ, Hadley M. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Arch Phys Med Rehabil. 1996;77(5):461-466.
⁸ Ivanhoe CB, Francisco GE, McGuire JR, Subramanian T, Grissom SP. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil. 2006;87(11):1509–1515.
⁹ Under specific conditions for 1.5 T and 3.0 T MRI scans. Refer to product labeling.

MEDIA CONTACT
Hyedi Nelson
Bellmont Partners
651-757-7054
hyedi@bellmontpartners.com

SOURCE Nura Pain Clinics